Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.

p16/p15 regulate the cell cycle pathway by inhibiting the cyclin Ds-CDK4/6 mediated phosphorylation of pRb. We reported previously that in T-cell acute lymphoblastic leukemia (T-ALL), p16 and p15 were frequently (approximately 70%) inactivated at the DNA level by deletion, mutation, or hypermethylation. Therefore, we hypothesize that inactivation of the cell cycle regulatory pathway may be essential in the pathogenesis of T-ALL, and that the remaining T-ALL with a wild-type p16/p15 gene likely harbor inactivation of these genes at RNA or protein levels. Alternatively, the downstream components of the pathway including CDK4/6, cyclin Ds, and pRb may be deregulated. In 124 primary T-ALLs, we found inactivation of the p16 and p15 genes at the DNA level in 79 (64%) and 64 (52%) samples, respectively. Only 9 of the 45 samples with wild-type p16 expressed p16 protein, whereas the remaining 36 lacked p16 expression at the RNA or protein level. In the 60 samples with an intact p15 gene, only 2 expressed p15 mRNA, and the only one analyzed lacked p15 protein. Overall, the abrogation rates for p16 and p15 at DNA/RNA/protein levels were 93% (115 of 124) and 99% (123 of 124), respectively. Although no alterations were evident in cyclin Ds or CDK4/6, pRb was hyperphosphorylated in the majority of samples investigated. These findings strongly support that both p16 and p15 are specific targets in the deregulation of the cell cycle pathway in T-ALL and that the inactivation of these genes is most likely essential in the pathogenesis of this disease.

[1]  D. Grandér,et al.  Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence , 1998, Oncogene.

[2]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[3]  S. Ogawa,et al.  Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. , 1996, Blood.

[4]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[5]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[6]  H. Koeffler,et al.  Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A , 1997, Leukemia.

[7]  M. Vidal,et al.  The retinoblastoma protein binds to a family of E2F transcription factors , 1993, Molecular and cellular biology.

[8]  M. Iravani,et al.  Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia , 1997, Oncogene.

[9]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[10]  A. Okamoto,et al.  Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Sigaux,et al.  Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. , 1996, Blood.

[12]  G. Hannon,et al.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Kumanishi,et al.  Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. , 1998, Cancer research.

[14]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[15]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[16]  G. Hannon,et al.  Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.

[17]  P. Pollock,et al.  CDKN2A/p16 is inactivated in most melanoma cell lines. , 1997, Cancer research.

[18]  W Arap,et al.  Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.

[19]  M. Link,et al.  Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. , 1997, Cancer research.

[20]  P. Meltzer,et al.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.

[21]  G. Peters,et al.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.

[22]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[23]  F. Ajchenbaum‐Cymbalista,et al.  Overexpression of cyclin D2 in chronic B-cell malignancies. , 1995, Blood.

[24]  J. Bartek,et al.  Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.

[25]  J. Decaprio,et al.  Cyclin E, a redundant cyclin in breast cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[27]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[28]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[29]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[30]  A. Look,et al.  Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. , 1993, Cancer research.

[31]  M. Diccianni,et al.  The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. , 1996, Cancer letters.

[32]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[33]  A. Okamoto,et al.  IS-12 Mutation and altered expression of P16^ in human cancer. , 1995 .

[34]  W. Hiddemann,et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. , 1997, Cancer research.

[35]  H. Kaneko,et al.  Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. , 1996, Leukemia.

[36]  N. Dyson,et al.  The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. , 1990, The EMBO journal.

[37]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[38]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[39]  N. Colburn,et al.  Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. , 1993, Oncogene.

[40]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[41]  M. Amylon,et al.  Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. , 1997, Leukemia research.

[42]  J. Decaprio,et al.  p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. , 1997, Blood.

[43]  C. James,et al.  CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.

[44]  B. Quesnel,et al.  Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation , 1996, British journal of haematology.

[45]  J. Herman,et al.  Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. , 1997, Cancer research.

[46]  F. Haluska,et al.  Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.

[47]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[48]  R. Sclafani,et al.  Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[50]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[51]  Steven K. Hanks,et al.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins , 1992, Cell.

[52]  Y. Hayashi,et al.  Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. , 1995, Blood.

[53]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[54]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[55]  K. Keyomarsi,et al.  Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Smith,et al.  Deletion or lack of expression of CDKN2 (CDK4I/MTS1/INK4A) and MTS2 (INK4B) in acute lymphoblastic leukemia cell lines reflects the phenotype of the uncultured primary leukemia cells. , 1996, Leukemia.

[57]  F. Kaye,et al.  A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Lapointe,et al.  A p18 mutant defective in CDK6 binding in human breast cancer cells. , 1996, Cancer research.

[59]  E. Harlow,et al.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.

[60]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[61]  M. Omura-Minamisawa,et al.  Frequent deregulation of p16 and the p16/G1 cell cycle‐regulatory pathway in neuroblastoma , 1999, International journal of cancer.

[62]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[63]  E. Livingston,et al.  Deletion of P15 (MTS2) in head and neck squamous cell carcinomas. , 1998, The Journal of surgical research.

[64]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[65]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.